The relation of serum myeloperoxidase to disease progression and mortality in patients with chronic obstructive pulmonary disease (COPD).
The relation of serum myeloperoxidase to disease progression and mortality in patients with chronic obstructive pulmonary disease (COPD).
复制标题
DOI：
10.1371/journal.pone.0061315
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Sin DD
中科院分区：
文献类型：
--
作者：
Park HY;Man SF;Tashkin D;Wise RA;Connett JE;Anthonisen NA;Sin DD
髓过氧化物酶是一种储存在中性粒细胞初级颗粒中的强氧化剂，具有强大的抗菌和致动脉粥样硬化特性。髓过氧化物酶与慢性阻塞性肺疾病(COPD)的发病机制有关。然而，髓过氧化物酶与慢性阻塞性肺疾病健康结局的关系还不是很清楚。在肺健康研究中，我们测量了4677名轻度到中度气流受限的受试者的血清髓过氧化物酶水平。使用COX比例风险模型，我们确定了血清髓过氧化物酶浓度与全因和疾病特定原因死亡风险的关系。我们发现，血清髓过氧化物酶浓度与1秒用力呼气量(FEV1)加速下降显著相关(p<；0.0001)，在调整了年龄、性别、种族、基线FEV1和吸烟状况后，这种相关性持续存在(p = 0.048)。血清髓过氧化物酶浓度也与心血管死亡风险增加相关(p = 0.036)。髓过氧化物酶最高五分之一的个体与最低五分之一的个体相比，心血管死亡率的危险比为1.9(95%可信区间为1.00-3.58；p = 0.049)，这在继续吸烟的患者中尤其显著(调整后的p值为0.0396)。然而，血清髓过氧化物酶浓度与总死亡率、呼吸系统死亡率或恶性肿瘤死亡无关。综上所述，血清髓过氧化物酶水平升高与COPD患者肺功能迅速下降和心血管预后不良有关，这支持髓过氧化物酶在COPD进展和心血管疾病发病机制中的新作用。
Myeloperoxidase is a strong oxidant stored in primary granules of neutrophils with potent antibacterial and proatherogenic properties. Myeloperoxidase has been implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). However, the relationship of myeloperoxidase to health outcomes in COPD is not well known. We measured serum myeloperoxidase levels from 4,677 subjects with mild to moderate airflow limitation in the Lung Health Study. Using a Cox proportional hazards model, we determined the relationship of serum myeloperoxidase concentration to the risk of all-cause and disease specific causes of mortality. We found that serum myeloperoxidase concentrations were significantly related to accelerated decline in forced expiratory volume in 1 second (FEV1) over 11 years of follow-up (p<0.0001), and this association persisted after adjustments for age, sex, race, baseline FEV1, and smoking status (p = 0.048). Serum myeloperoxidase concentrations were also associated with increased risk of cardiovascular mortality (p = 0.036). Individuals in the highest quintile of myeloperoxidase had a hazard ratio of cardiovascular mortality of 1.90 (95% confidence interval 1.00–3.58; p = 0.049) compared with those in the lowest quintile, which was particularly notable in patients who continued to smoke (adjusted p-value of 0.0396). However, serum myeloperoxidase concentration was not related to total mortality, respiratory mortality, or deaths from malignancies. In conclusion, increased serum myeloperoxidase levels are associated with rapid lung function decline and poor cardiovascular outcomes in COPD patients, which support the emerging role of myeloperoxidase in the pathogenesis of COPD progression and cardiovascular disease.
登录
查看更多内容
影响因子：
37.8
作者：
Baldus, S;Heeschen, C;Hamm, CW
通讯作者：
Hamm, CW
影响因子：
56.9
作者：
KLEBANOFF, SJ
通讯作者：
KLEBANOFF, SJ
影响因子：
10
作者：
Pinto-Plata, Victor;Toso, John;Celli, Bartolome
通讯作者：
Celli, Bartolome
影响因子：
5.8
作者：
Parr DG;White AJ;Bayley DL;Guest PJ;Stockley RA
通讯作者：
Stockley RA
DOI：
10.1164/rccm.201105-0831oc
发表时间：
2011-11-01
影响因子：
24.7
作者：
Casanova, Ciro;de Torres, Juan P.;Celli, Bartolome R.
通讯作者：
Celli, Bartolome R.